GE HealthCare Launches AI-Powered Invenia ABUS Premium for Faster, More Accurate Cancer Detection in Dense Breasts
Introduction
GE HealthCare has announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, a groundbreaking 3D ultrasound system designed to enhance breast cancer detection in women with dense breast tissue. Equipped with advanced artificial intelligence (AI) and several innovative features, Invenia ABUS Premium aims to streamline the screening process, improve exam readings, and provide clinicians with faster, more reproducible results. The new system promises to enhance early cancer detection, a critical step in improving patient outcomes.
The Challenge of Dense Breasts
Dense breast tissue is a significant challenge in breast cancer screening. Approximately 71% of cancers occur in dense breasts, and studies have shown that 40% of women and 70% of Asian women have dense breast tissue. Dense breasts make it more difficult for mammograms to detect cancer, as tumors can be hidden within the dense tissue. As a result, women with dense breasts are four to six times more likely to be diagnosed with breast cancer.
According to medical studies, one-third of cancers in dense breasts can go undetected by mammograms. This highlights the growing need for supplemental screening methods that can provide clearer, more detailed images. In this context, ABUS technology has emerged as an invaluable tool, as it can detect invasive cancer with greater sensitivity when used in combination with mammography.
The Role of AI in Invenia ABUS Premium
The Invenia ABUS Premium system integrates advanced AI to optimize breast cancer detection in dense breasts. With its AI-powered tools, the system can significantly improve screening efficiency and clinical confidence. In particular, the system includes Verisound™ AI, which helps clinicians assess scan quality in real-time. This tool provides immediate feedback on proper breast coverage and positioning, ensuring that the exam is conducted optimally.
Invenia ABUS Premium also features Auto Nipple Detection, a tool that automatically identifies the position of the nipple marker during the scan. This feature streamlines the scanning process and reduces the chances of human error, ensuring consistent and accurate results.
GE HealthCare Launches AI-Powered Invenia ABUS Premium for Faster, More Accurate Cancer Detection in Dense Breasts
Enhanced Speed and Scan Quality
Speed and image quality are crucial factors in improving both the patient and clinician experience. The new Fast Scan tool in Invenia ABUS Premium accelerates scan time by up to 40%, helping clinicians manage high patient volumes more efficiently. Additionally, the system’s cSound™ Imageformer automatically focuses on every pixel, ensuring that image quality remains consistent and high-resolution throughout the entire scan. This improves the reproducibility of results, which is key to monitoring patient progress over time.
For clinicians, the Invenia ABUS Viewer with AI Assistant offers a fast, streamlined way to review and interpret patient exams. Using AI tools, the system can assist in detecting and characterizing breast lesions, further enhancing diagnostic accuracy. This AI integration helps reduce the workload on clinicians, addressing the issue of staff shortages, which has become a pressing concern in the healthcare sector.
Improving the Patient Experience
One of the standout features of the Invenia ABUS Premium is its patient-friendly design. The system’s non-invasive nature eliminates the need for radiation or contrast agents, providing a safer alternative to traditional mammography. This feature reduces the risk of unnecessary exposure to ionizing radiation, which is a concern for many patients undergoing routine screenings.
A study of patient experiences revealed that 100% of women would recommend an ABUS exam to a friend, indicating the high level of satisfaction with the procedure. The system’s Reverse Curve™ transducer is specifically designed to follow the natural contours of a woman’s breast anatomy, improving comfort during the exam. Additionally, adjustable compression levels allow for a personalized experience, ensuring that patients feel more at ease during the procedure.
Dr. Athina Vourtsis, Chief Director and Founder of Athena Medical in Athens, Greece, praised the Invenia ABUS Premium for its improvements in both patient comfort and diagnostic quality. “The new Reverse Curve transducer makes the examination more patient-friendly, and it is much more comfortable,” Dr. Vourtsis noted. “There has been a great improvement in image quality, with less shadowing, and the structures behind the area of the nipple are seen more clearly. This provides radiologists with greater diagnostic confidence.”
The Potential to Reduce Unnecessary Biopsies
In addition to improving comfort and speed, Invenia ABUS Premium has the potential to reduce unnecessary biopsies. By providing highly detailed images, the system can help distinguish between benign and malignant tumors more accurately. This allows clinicians to escalate care more promptly, ensuring that patients receive the appropriate treatment without undergoing unnecessary invasive procedures.
Launch and Availability
The Invenia ABUS Premium is set to launch in key countries throughout 2025. The system has already received Premarket Approval (PMA) from the U.S. Food and Drug Administration, signifying its readiness for clinical use. It was recently featured at the 2025 European Congress of Radiology (ECR) and will also be showcased at the National Consortium of Breast Centers (NCoBC) 2025 and the Society of Breast Imaging (SBI) Symposium later this year.
Conclusion
The launch of Invenia ABUS Premium by GE HealthCare represents a significant advancement in the field of breast cancer screening, particularly for women with dense breast tissue. With its AI-powered tools, fast scanning capabilities, and improved patient comfort, the system offers a comprehensive solution for detecting breast cancer at earlier stages, when treatment outcomes are more favorable. As the technology continues to evolve, it has the potential to transform breast cancer care, improving the diagnostic process for both patients and clinicians alike.
Learn more about GE HealthCare’s Invenia ABUS Premium here: Invenia ABUS Breast Imaging Ultrasound | GE HealthCare (United States)
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
